[Skip to Content]
[Skip to Content Landing]
Article
March 24, 1997

Effects of Weight Loss and Sodium Reduction Intervention on Blood Pressure and Hypertension Incidence in Overweight People With High-Normal Blood Pressure: The Trials of Hypertension Prevention, Phase II

Arch Intern Med. 1997;157(6):657-667. doi:10.1001/archinte.1997.00440270105009
Abstract

Objective:  To provide a firmer basis for preventing high blood pressure (BP), we tested interventions to promote weight loss, dietary sodium reduction, and their combination for lowering diastolic BP, systolic BP, and the incidence of hypertension during a 3- to 4-year period.

Methods:  We conducted a randomized, 2X2 factorial, clinical trial, with BP levels measured by blinded observers. Nine academic medical centers recruited 2382 men and women (age range, 30-54 years) not taking antihypertensive drugs, with a diastolic BP of 83 to 89 mm Hg, a systolic BP lower than 140 mm Hg, and a body mass index (the weight in kilograms divided by the square of the height in meters) representing 110% to 165% of desirable body weight. Counseling aimed at helping participants achieve their desirable weight or a 4.5-kg or more weight reduction (in the weight loss and combined groups) and/or sodium intake of 80 mmol/d (in the sodium reduction and combined groups) was provided.

Results:  From baseline, participants' weight decreased by 4.3 to 4.5 kg at 6 months and by approximately 2 kg at 36 months in the weight loss and combined groups compared with weight changes in the usual care group (all groups, P<.001). Sodium excretion decreased 50 and 40 mmol/d at 6 and 36 months, respectively, in the sodium reduction group and about 15 mmol/d less at each time point in the combined group compared with the usual care group (all groups, P<.01). Compared with the usual care group, BP decreased 3.7/2.7 mm Hg in the weight loss group, 2.9/1.6 mm Hg in the sodium reduction group, and 4.0/2.8 mm Hg in the combined group at 6 months (all groups, P<.001). At 36 months, BP decreases remained greater in the active intervention groups than in the usual care group (weight loss group, 1.3/0.9 mm Hg; sodium reduction group, 1.2/0.7 mm Hg; combined group, 1.1/0.6 mm Hg). Differences were statistically significant for systolic and diastolic BP in the weight loss group and for systolic BP in the sodium reduction group. Through 48 months, the incidence of hypertension (BP ≥140 mm Hg systolic or ≥90 mm Hg diastolic or the use of antihypertensive drugs) was significantly less in each active intervention group than the usual care group (average relative risks, 0.78-0.82).

Conclusions:  In overweight adults with high-normal BP, weight loss and reduction in sodium intake, individually and in combination, were effective in lowering systolic and diastolic BP, especially in the short-term (6 months). Although the effects on average BP declined over time, reductions in hypertension incidence were achieved.Arch Intern Med. 1997;157:657-667

References
1.
Whelton PK, Brancati F, Appel LJ, Klag MJ.  The challenge of hypertension and atherosclerotic cardiovascular disease in economically developing countries .  High Blood Pressure Cardiovasc Prev. 1995:4:36-45.
2.
Whelton PK.  Epidemiology of hypertension .  Lancet. 1994;344:101-106.Crossref
3.
Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure.  The Fifth Report of the Joint National Committee on the Detection, Evaluation, and Treatment of High Blood Pressure (JNC V) .  Arch Intern Med. 1993;153:154-183.Crossref
4.
Hebert P, Moser M, Mayer J, Glynn RJ, Hennekens CH.  Recent evidence on drug therapy of mild to moderate hypertension and decreased risk of coronary heart disease .  Arch Intern Med. 1993;153:578-581.Crossref
5.
MacMahon S, Cutler JA, Stamler J, et al.  Antihypertensive drug treatment: potential, expected, and observed effects on vascular disease .  Hypertension. 1990; 335:827-838.
6.
Coresh J, Whelton PK, Mead LA, Levine DM, Klag MJ.  Increased cardiovascular disease risk in treated hypertensive men .  J Hypertens. 1994;12:S73. Abstract.
7.
Stamler J, Stamler R, Neaton JD.  Blood pressure, systolic and diastolic, and cardiovascular risks: US population data .  Arch Intern Med. 1993;153:598-615.Crossref
8.
Working Group on Primary Prevention of Hypertension.  Report of the National High Blood Pressure Education Program Working Group on Primary Prevention of Hypertension .  Arch Intern Med. 1993;153:186-208.Crossref
9.
The Hypertension Prevention Trial Research Group.  The Hypertension Prevention Trial (HPT): three-year effects of dietary changes in blood pressure .  Arch Intern Med. 1990;150:153-162.Crossref
10.
Stamler R, Stamler J, Gosch KC, et al.  Primary prevention of hypertension by nutritional-hygienic means: final report of a randomized, controlled trial .  JAMA. 1989;262:1801-1807.Crossref
11.
Applegate WB, Borhani NO, Cohen J, et al, for the Trials of Hypertension Prevention (TOHP) Collaborative Research Group.  Trials of Hypertension Prevention, Phase I design .  Ann Epidemiol. 1991;1:455-471.Crossref
12.
The Trials of Hypertension Prevention Collaborative Research Group.  The effects of non-pharmacological interventions on blood pressure of persons with high normal levels: results of the Trials of Hypertension Prevention (Phase I) .  JAMA. 1992;267:1213-1220.Crossref
13.
Stamler R.  Implications of the INTERSALT Study .  Hypertension. 1991;17 ( (suppl I) ):I-16-I-20.Crossref
14.
Cook NR, Cohen J, Hebert P, Taylor JO, Hennekens CH.  Implications of small reductions in diastolic blood pressure for primary prevention .  Arch Intern Med. 1995;155:701-709.Crossref
15.
Hebert PR, Bolt RJ, Borhani NO, et al, for the Trials of Hypertension Prevention (TOHP) Collaborative Research Group.  Design of a multicenter trial to evaluate long-term lifestyle intervention in adults with high-normal blood pressure levels: Trials of Hypertension Prevention (Phase II) .  Ann Epidemiol. 1995;5:130-139.Crossref
16.
Hollis JF, Satterfield S, Smith F, et al, for the Trials of Hypertension Prevention (TOHP) Collaborative Research Group.  Recruitment for Phase II of the Trials of Hypertension Prevention: effective strategies and predictors of randomization .  Ann Epidemiol. 1995;5:140-148.Crossref
17.
Wright BM, Dore CF.  A random-zero sphygmomanometer .  Lancet. 1970;1:337-338.
18.
Metropolitan Life Insurance Co.  1983 Metropolitan height and weight tables .  Stat Bull Metrop Life Found. 1983;64:3-9.
19.
Lasser VI, Raczynski JM, Stevens VJ, et al, for the Trials of Hypertension Prevention Collaborative Research Group.  Trials of Hypertension Prevention, Phase II: structure and content of the weight loss and dietary sodium reduction interventions .  Ann Epidemiol. 1995;5:156-164.Crossref
20.
Stevens VJ, Corrigan SA, Obarzanek E, et al, for the Trials of Hypertension Prevention (TOHP) Collaborative Research Group.  Weight loss in Phase I of the Trials of Hypertension Prevention .  Arch Intern Med. 1993;153:849-858.Crossref
21.
Searle SR.  Linear Models . New York, NY: John Wiley & Sons Inc; 1971.
22.
Cook NR, Ware JH.  Design and analysis methods for longitudinal research .  Annu Rev Public Health. 1983;4:1-23.Crossref
23.
Kalbfleisch JD, Prentice RL.  The Statistical Analysis of Failure Time Data . New York, NY: John Wiley & Sons Inc; 1980.
24.
Appel LJ, Hebert PR, Cohen JD, et al, for the Trials of Hypertension Prevention (TOHP) Collaborative Research Group.  Baseline characteristics of participants in Phase II of the Trials of Hypertension (TOHP II) .  Ann Epidemiol. 1995; 5:149-155.Crossref
25.
Cutler JA, Follmann D, Elliott P, Suh I.  An overview of randomized trials of sodium reduction and blood pressure .  Hypertension. 1991;17( (suppl I) ):I-27-I-33.Crossref
26.
Cutler JA.  Randomized clinical trials of weight reduction in nonhypertensive persons .  Ann Epidemiol. 1991;1:363-370.Crossref
27.
Elmer PJ, Grimm RH Jr, Flack J, Laing B.  Dietary sodium reduction for hypertension prevention and treatment .  Hypertension. 1991;17(suppl I):I-182-I-189.
28.
Reisin E.  Obesity hypertension: nonpharmacologic and pharmacologic therapeutic modalities . In: Laragh JH, Brenner BM, eds.  Hypertension: Pathophysiology, Diagnosis, and Management . 2nd ed. New York, NY: Raven Press Ltd; 1995.
29.
Reaven GM, Lithell H, Landsberg L.  Hypertension and associated metabolic abnormalities: the role of insulin resistance and the sympathoadrenal system .  N Engl J Med. 1996;334:374-381.Crossref
30.
Kuczmarski RJ, Flegal KM, Campbell SM, Johnson CL.  Increasing prevalence of overweight among US adults: the National Health and Nutrition Examination Surveys, 1960 to 1991 .  JAMA. 1994;272:202-211.Crossref
31.
Stamler J.  Dietary salt and blood pressure .  Ann N Y Acad Sci. 1993;676:122-156.Crossref
×